Search academic texts

Information × Registration Number 0221U106470, 0121U107508 , R & D reports Title 620. Personalization of the treatment and development of new biologically active substances in optimization of pharmacotherapy of a few socially important diseases popup.stage_title Head Antonenko Petro В., д.мед.н. Registration Date 07-12-2021 Organization Odessa National Medical University popup.description2  Among the patients with pulmonary tuberculosis (TB), the “intermediate metabolizers” according to CYP3A4 *1B genotype was more often observed than among healthy volunteers. In individuals with “slow metabolizers” genotype of CYP3A4*1B the treatment outcome was quite better, than in “rapid metabolizers”. Thus in “slow metabolizers” according to CYP3A4*1B and CYP3A4*1G genotype the initial hepatic function was better than in other patients. completion of in-patient stage of anti-TB treatment the level of cytolysis and toxicity indexes was much higher than in fast metabolizers. That is why detection of CYP3A4*1G genotype of TB patients at the beginning of TB treatment could help to recognize a group of the individuals with increased risk of liver injury during therapy. That is why the “slow metabolizers” genotype is a prognostic sign of putative hepatotoxicity during anti-tuberculosis therapy. Current research are fulfilled according to planning task of Ministry of Health of Ukraine Product Description popup.authors Antonenko Kateryna O. Antonenko Petro B. Helmboldt Volodymyr О. Kovalchuk Iryna Kresyun Valentyn Yo. Lytvynchuk Iryna V. Lobashova Katerynа H. Poludenko Hanna O. Prystupa Bohdan V. Razkevych Olesia S. Rozhkovsky Yaroslav V. Shemonayeva Katerynа F. Shyshkin Ivan O. Yunusova Saida I. popup.nrat_date 2021-12-07 Close